Management
In a retrospective study of 603 lung transplant recipients, only one patient (0.2%) discontinued iABLC therapy due to a drug-attributable adverse event [PMID:35506698].
Complications
Among 603 patients receiving iABLC prophylaxis, only one patient (0.2%) experienced a drug-attributable adverse event leading to discontinuation [PMID:35506698].
Prognosis & Follow-up
In the study cohort, one-year adverse events including rejection (68.7%), graft loss, and death (13.3%) matched national outcomes [PMID:35506698].
References
1 Huggins JP, Pease R, Stanly K, Workman A, Reynolds J, Alexander BD. Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients. Antimicrobial agents and chemotherapy 2022. link
1 papers cited of 4 indexed.